Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Viridian Therapeutics First Quarter 2023 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to hand the call over to Ms. Louisa Stone, Manager of Investor Relations for Viridian. Please go ahead.

Louisa Stone

everyone, first welcome, conference XXXX and call. you, to quarter our earnings Thank reporting and website financial available press our The release results Investors of on page corporate our www.viridiantherapeutics.com. corporate at the is updates

and President, Officer; Chief the Officer; on Vice Dr. and James, Affairs our are our Kristian this Joining Development Rajagopalan, Investor Todd Relations. Chief and our Senior me Officer; Business call Executive Financial Strategy our Officer; Deepa and Scott and Thomas afternoon Corporate Myers, Ciulla, President Dr. Chief Product Humer, Chief

differ Before this risks we these and plans SEC. financial product will to actual uncertainties most and statements begin, our everyone CEO. file turn and I call now regulatory, Form would A those like cause from be the to can commercialization results our conference found with forecasted. to contain would on research risks President XX-K that to could remind in activities. regarding outlook Myers, that description to and our materially webcast in to These the addition XX-Q call and statements and recent development subject like I forward-looking Scott of are over

Scott Myers

areas best-in-class future. far patients progress is quarter, includes joining important our report completing looking that of Thank the afternoon, thyroid continuing Good everyone. our therapies a company Thanks forward an in year all X I potential thus months additional disease excited proud year on first my for and with a to and all I'm key programs. and today. you, XXXX We President bring to work had disease for productive CEO. our progress eye our milestones in Louisa. after am Viridian, and to us of today Viridian's has as made clinical the to

throughout success. senior us on first to has quarter, key team, team rapidly grown leadership position for made we our future several Our and helping the hires strategically

Program earlier Dr. Development issued Medical Dr. Officer; hires Tony release Vice be Chief the of Senior include Erik for be Chief Each can Geissler, as made the company in found as already have to today, we Additional Casciano, to Officer; but leaders Viridian's mature will Felix press integral prepare organization our and we continue Ciulla, details Commercial Tom Kupperman, Affairs; President of organization first these these leadership. our Dr. and valuable an future teams, for Vice President, individuals and success. contributions expand

programs we our discuss I'll Kristian the clinical during now questions. and in will review we take first CFO, your progress before results financial Humer, made quarter, our the our

TED humanized IGF-XR. factor of lead starting our programs, antagonist intravenously acts VRDN-XXX, as which full insulin-like our with with asset, administered a a I receptor, once growth begin X Let's monoclonal every antibody weeks, or

of Based of clinical TED. evaluate half regimen we XX-week which announcements TEPEZZA. in regimen community, active key the treatment FDA of cohorts in safety evaluating of compared team TED Phase X topline our In and the efficacy discussions stakeholders the III particular the of efficacy is safety patients our VRDN-XXX for on trial, the VRDN-XXX will approved and with X-dose X-dose shortened enthusiasm recent XX-week with our THRIVE with there XXXX XXXX, dose the of at this from and a positive second VRDN-XXX the global year, the with active initiated In series December in I/II patients reported TED. beginning Phase data trial, of clinical of

and to we reporting the convenience to treatment in continue has their by of provide is to line the results ongoing, center. an to shortening X and eliminating the welcome from potential anticipate infusion Enrollment arm patients Success middle top X-dose THRIVE course trips in XXXX.

patients evaluating with IV is that our in announce to VRDN-XXX study excited are fully we TED, chronic TED to chronic Moving proof-of-concept enrolled.

VRDN-XXX, of used in the design in design safety to we X of one day our clinical that evaluation is reminder, day similar week proof-of-concept activity the second Two at chronic and TED a X. trial active at with XX at infusions As and TED.

mg are Inclusion favor patients VRDN-XXX XX clinical Randomized baseline. dose There each X criteria kg X:X will and enrollment in placebo. target of per cohorts, cohort. include versus score kg X in per any activity of at X mg

trial We report to cohorts of this results both dose expect from July. either June or proof-of-concept in

the expected Following chronic III efficacy end XXXX. patients of our by self-administered to to programs, TED. start delivery access, I'd now TED. to which expand be the for THRIVE-X safety device, potential burden results, patients VRDN-XXX like a Phase Topline our in reduce move subcutaneous could VRDN-XXX, developed THRIVE-X, include have the and with for we which results global increase and patient-friendly with VRDN-XXX plan treatment second X to of pen trial, with from to living evaluate candidates All options are the VRDN-XXX. and significantly

clinical the We of patients. work, mechanisms differentiated end plan the full we the antagonism a the many before to that product these them of VRDN-XXX as most by lead candidates and of subcutaneous preclinical believe either select VRDN-XXX likely to action learnings bring make IV IGF-XR With one our program subcutaneous from VRDN-XXX of of achieved to with year. our and best-in-class

backup lead a and XXXX VRDN-XXX. in end of This steadfastly on As subcutaneous year. proceed allows keep program VRDN-XXX a evaluating only trial efforts patients advancing to VRDN-XXX with potential in if a focusing VRDN-XXX result, with selected while as the our at as is will TED us the the VRDN-XXX

the I selection lead to will get highlight priorities by now program year-end. upcoming subcutaneous the

the in I in Phase results fourth expected of VRDN-XXX, volunteers quarter XXXX. are For healthy

For generate from healthy VRDN-XXX, I to Phase continue we the data ongoing trial. volunteer

application second the the investigational track during on quarter. our with VRDN-XXX, For remain new drug file plans FDA the to

subcutaneous II/III fourth middle I program healthy Phase the the selected, we of to of expect Phase the in planned advance which XXXX. lead quarter candidates volunteers a XXXX. results in After to pivotal expect is the for We trial,

on our programs development. in new featured I/II research thrilled month, This the featured preclinical an was the Research platform multiple from research Phase first Ophthalmology to VRDN-XXX. the of A marked that TED, Last milestone at Association congress, at data poster of VRDN-XXX and VRDN-XXX in of abstracts medical present Meeting. active XXXX with company's a our team exciting trial Vision presentation Annual and VRDN-XXX presentation while clinical and presentations patients

Our presenting year. engaging additional this team looks physician further and medical congresses communities and throughout TED with at forward to patient

advance we preclinical Finally, to disease will rare our pipeline and space. and and continue the earlier-stage TED into expand beyond our autoimmune focus

will system XXX utilize preclinical of preclinical include and to provide Yesterday, partnership With programs. provide over of information on one drug a at our review least with We the I one for Injections turn additional that, plan VRDN-XXX, Our to first financial quarter Kristian? call programs later enFuse for programs we this announced who year. will XXX. their XXXX. the delivery on-body of a the Kristian, to Enable

Kristian Humer

and second million with credit to in XX, half our current cash, and December will that you opportunity refer a of short-term review equivalents Thank of you, everyone. into million a afternoon, quarter take today sufficient fund ended $XXX.X detailed Good the XXXX. to be quarter few our with financial of our first the million for and press like earlier excluding our facility believe issued investments I'd as compared operations items. our cash, We $XXX.X first short-term equivalents this $XX the release We Scott. XXXX results summary to cash XXXX. to investments, for approximately cash

expenses first in period of IND expenses compared of XXXX Research consideration to increase the last for Other Enable expenses VRDN-XXX for and research upfront the and and the payment same XXXX as rights development Research development utilize on-body activities. include drivers first with $XX.X one-time system. expenses for for $XX.X the a drug application the for for granted delivery include well year. higher were CMC preparation to development quarter the Viridian million as enFuse Enable $XX Injections' development million quarter to million during in in

Higher higher preclinical personnel headcount, an collaboration increase to due due early-stage to costs costs in expenses.

I'll shares an stock X, had May approximately operator as-converted With to questions. million call the common on the for XX Viridian of that, basis. As open of XXXX, Operator? ask outstanding

Operator

Instructions] from with is Fargo. Archila [Operator of first Your Derek the Wells line question

Derek Archila

quarter the can in questions just on chronic just the And Congrats on us. versus variables progress. Maybe out then Horizon do lead of coming your ongoing has data chalk market? just -- think their with that we from you anything kind second you talk July quarter? the things just thinking Maybe from to up the the that opportunity do Amgen about I given the Or in market what mean also, two TED saw in first, in could going changed the recently deal? results. you deal-related

Scott Myers

activity it's in clinical able We're real going see This by because been Horizon proptosis. a the TED probability meaningful They X-millimeter were response expecting recent with in to is very Scott. and a XX% to chronic that high post data. we're reduction a confirmed

reduction We're very and with millimeters, would pleased plan VRDN-XXX in per the with still because only activity the than Our to establish trial of less very is what's still X -- proptosis overenrolled evaluating the excuse mg THRIVE-X. evaluate to proof concept We've happened of kg meaningful doses X X that of actually be we cohort. me, trial. doses longer in be the in

really make rolling from be the the look to and the either So to ready that sure in information we sites, need process CRO, get we'll or through announce June time the the once bring July. then right. we where from And it's some MRIs, all going to we're

from population. when We the the baseline July look more to the actually intervention treatment. Horizon regard our very points a chronic to and reporting data information TED, chronic then surgical data systemic what release all efficacy question in this it their was in there's or data placebo-controlled end a thought large have left, And June they forward because the we suffering of with in year. data. really able then seeing unless your of patient some very and was to about And first this this in they is unmet saw because forward patients population to second are safety that some was for they need good of use still look around we We characteristics,

a It patients reminder, themselves X study as cash. did that was differently. And presented excuse after and year a or to symptoms with normal reminder, for our was Horizon to for greater up we -- X not used than we equal had study study set of a screening values me, just or X then above of proptosis And a prior slightly requirement cash screening. whereas have X were though, millimeters --

there's to at X it cohort there enrolling cohorts, and mentioned the kg enrollment, X:X I follow overenrolled. mg enrolled per kg mg the kg before, I said cohort as versus and per as a X VRDN-XXX, with X first XX with was are staggered mg a was We per XX placebo, arm randomized

X weekly. And q.X day then and results at XX of only in be week there's those XX, again is then infusions day which at day X X. So the each and at will

think that well with in and result X-millimeter We that data. the So companies reduction decisions coverage label good Horizon their will really tailwind help create news with that, that more broader from them the will from the market. and a that marketplace will play get hopefully for their nice insurance

Todd James

Todd. is this Derek,

far to we direct-to-consumer helpful advertising as of was and to was potential was QX to not the But an as I well As that from as to expanding the as trying reduction taking to point, sales a a in process when patient support M&A in-flight trajectory how far or the things reimbursement sales great as you're in. that impacting absolutely place access market far for physician and is the around their investing your as expedite in to potentially sales Horizon impact be what as invest new market headlines, trying operational patients around changes potentially places could drug. public certainly the driving as make distraction around think QX, think force

marketplace. also that Scott additional aware far integration have able the data just just out either. chronic as and in physicians certainly and to I'd as chronic sales hopefully that point The help educate isn't being easy payers will described to drive But

to couple early changes year then And were so either or think those integrating that next able we And to the people quarters up impact with and of sales be I pick Horizon see additional should some year this made, again. should as being TEPEZZA later expect the return over team. probably growth chronic, the is next Amgen

Operator

Stifel. Your question with is line Thomson next from the Alex of

Unidentified Analyst

commercial for so, successful And faster? label? trials you PK couple Maybe you question, whether TEPEZZA impact market opportunity? about your the the new have follow-up bridge around to to path how get expectations in talk with as XXX label? a a old if expect to maybe to guess sort I path might could the that forward current are subcu upon do your Derek's Do the what Or IV expect then you label for if me. And you the get of approval? potentially you the forward

Scott Myers

So for THRIVE-X supportive to study and of BLA. the second going the THRIVE are one, the be both the

would And label TEPEZZA you're similar with a TED we today that so then into then broad the to what translate expect label. to seeing

question? could sorry, repeat And you your first

Unidentified Analyst

With subcu. the XXX

Scott Myers

So way of programs we're separate is really subcu. current it the that thinking IV about versus

with currently, that plans affinity on now. the going that's candidate to extension us the which XXX moving to the up no lead everything something to bridge And from evaluate ahead way an looks for so XXX today, right it we're half-life But approval set THRIVE update seeing If -- to of and of subcu, certainly binding XXX subcu, would we're the there with with of we're then you were in that IV IV, along from based to and the we'll the for off select have from future. THRIVE-X best profile subcu like in XXX. a

Operator

Your Gavin the next line is Clark-Gartner. from question of

Gavin Clark-Gartner

had I two.

make work. come just And select do I'll potentially preclinical any manufacturing my that for that wondering First, slow back specifically toxicology I or formulation if there's wanted to question. nothing second about could down, XXX, sure you you else

Scott Myers

through year. on And will All underway the right with to year. now, healthy The continue complete or and three them going the will by studies the to formulation No. are issues work. of volunteer track, of end no there's we're and programs of evaluate preclinical the as end Yes. be the

Todd James

track on We to be middle a the what next track, as is other program pivotal Todd. -- should And this II/III Phase on lead of then for we start is selected then in be should the year. Gavin

Gavin Clark-Gartner

that preclinical an Or super for going just is unveiled? that I be program still to the right. discussed? announced earlier All that system that's be helpful. on separately, That's next And program was the on-body yesterday. then was wanted for that partnership clarify, to the is to preclinical for

Scott Myers

for to and will whatsoever. it developing, of That's we're nothing X currently the TED X with have programs do

it of will be those X. for So X

Operator

Your next Smith with question SVB is Thomas from of the line Securities.

Thomas Smith

wondering could point and into enrolling I initial is of enrollment a of wondering the characteristics was that relative if your criteria CAS A provide end. and between THRIVE you was patient is our on a sort any I if couple study your secondly, a at color tracking chronic whether I is the the the this additional And the population? on of and inclusion population this you how Horizon tracking difference understand more to low have how of trial study, the modeling? but just between baseline character then visibility or towards concept mid cohort CAS kind of any

Scott Myers

Yes.

XX the study, So in back can pleased but globally, to first regard with placement we we're THRIVE we're we enrolled have really was that announce And than activated December. the more we interim sites not have, -- but not. second have we around any enrollment. they baseline the characteristics. the don't giving I updates that -- And we on not question our unblinded have believe was that

Operator

is line Chico of question the Securities. next with Wedbush Laura from Your

Laura Chico

two. have just I

the executing following understanding the enFuse up of why program for TED, outside on on now. delivery is rationale other kind curious the system, kind this of just for this programs Just but of right and

advantages levers Just you that. cash were criteria then any selecting on this terms to the for color any additional of in or particular secondarily, looking there commentary on extend partner? runway, or just And

a to correctly reading year. bit the the understand little up things picked R&D for the think on I'm remainder burn just here. of trying I if expectations I'm the

Scott Myers

Yes.

answer and So Kristian your -- is second this Scott. question the I'll take take first question. I'll the will

really or hard that a of safety been potentially can this philosophy one to improve in that, if dear delivery. criteria take Kristian? or that of preclinical and will this care our three created and believe help around the technology we near we look to is compound is market the Those are efficacy the goes that's the first the around mode of put within do So be and pipeline. going we and hallmark company that

Kristian Humer

So a million. bit $XXX look, we've under cash got little

-- way THRIVE-X, guide and bit continue THRIVE a second the cash program-by-program runway at but 'XX. it and end basically the of both of into all little XXXX, basis, to the funds We on it 'XX half data into through a funds

to forward into Our where this date at to that pivotal what the pivotal of at prep we're Most trials. move end will subcu program program of year, we is into funded pivotal so trial select end the 'XX decision calling the funded of through trials. point move we can the importantly, is expeditiously

to programs through is one, selection what to and pipeline want decide market non-TED either you these we'll expect or unveil funded IND all by they to fund. should let filing, us one Our candidate the and

at We -- usually our million. of QX have they programs chart pipeline due non-TED slightly programs -- of the expenses least payment rest XXXX. course enabled of are unveiling over to of operating the of $XX to of kind Kind pipeline in on X higher cash of our our the our X the committed one mostly on were than

as You somewhere in that steady expenses kind million. of we initiate a kind again should of slightly state $XX should elevated to between QX And expect again after THRIVE-X. back and million of normalize $XX

Operator

next with Riley Securities. line of question Patel from Kalpit is Your the B.

Kalpit Patel

are eye in Or KOLs chronic build severity do like space, be would market setting And disease. of a in saw Maybe setting? lower the that be a is on the it more backlog disease? treated? given for this we there conversations a think in on sort with slow the rapid the you I the it guess, uptake acute waiting will here of one opportunity your to TED thyroid based patients be that of

Scott Myers

a been lately in at add conferences will our color maybe learning field and quite part KOLs, and different little I'll actually This about with is visiting the the that. PIs Ciulla we've bit Scott. and out take first the a and Tom because

I was of fruit lines chronic that think the low-hanging in of the patients. situation is spoke actives. there I with, with some belief of a the are there physicians words the But

I coverage think forward, decision. the well there take with I their and get they recent to mentioned bodes as data that's label broad been that put can now out before,

subcu that's think we X-dose grow see to we about part I opportunity the of But significant The to when potential there really that's there's that, as think especially out And available. excited and we the regimen the THRIVE our market the with really market market our about for our physicians -- already X-dose have grow study. even I think are really versus opportunity offering.

have excuse use to approach diseases broad So a want very this whether to with treating a we'll IV -- disease, subcu. people me, or an

then patients sort there's than TEPEZZA, these criteria even and it's after of chronic be having Tom, a themselves definitely present because getting And and the to the longer years, I X a don't future know also are around now to that, of they even disease treatment disease of do add and for we've still lot telling their TEPEZZA data color? an heard you acute some if physicians relief. But are chronic XX X showed that appears with what the doses to us want

Dr. Thomas Ciulla

This Tom Ciulla. is Sure.

of And enthusiastic ascending dose presentations uniformly, mentioned, where KOLs. of has Neuro-Ophthalmology Orbital our and acute these proof-of-concept American congresses. actually Scott as investigators and about Vision at attended and the they're been has and very congresses So at we in study We Scott North Society the TED. through met each Society in of America we've for multiple with had Academic we -- several were multiple Research a North variety the recently. Surgeons, Association Ophthalmology, the of

positive they a and indeed gotten about we've lot feedback see of lot to patients told from chronic for as What the also about in data TED. do part think TED, suffering KOLs and backlog of as that many patients investigators. We've win take gotten recent have trial -- clinical that investigators a this data. Horizon's of we have and I feedback asked them have our positive us a they is of chronic a in

of a think there's TED, optimism, for where you only not active just there a asked groundswell about. for as TED, is we but backlog, So chronic

Kalpit Patel

right -- of maybe subcu us Okay. start give in steps pivotal What between selection little the and to can start more Got timing it. the a And that that the mid-XXXX. more trial? of color of are candidate you trial remaining the

Scott Myers

Yes.

some have move are conferences. volunteer at of seek we'll XXX there now, one -- the by based would forward and at the couple the the all we healthy the and with. plan then and studies, looking reported candidates And safety. XXX even bioavailability to on make input be healthy of the decision is volunteer of to a up So which then wind early be and right information, out about Those the and of And that trial will year, recent that we've which stakeholders XXX one then ongoing the information studies the will we from of completed enough end that information, would midyear. then start more

Operator

Butler Securities. Your next the Jason JMP is question from line with of

Jason Butler

pointed you for just guess, before IV. treatment the how TED to planning for your I the program? Scott, pivotal you the subcu study the the thinking Can THRIVE importance rolls chronic also and to duration over shortened program that the talk of in about

Scott Myers

Yes.

and is not not where you using see how are give compound, being and it are would going learning pathway way an as and paradigm the using how kind before, of has about of in that changed launch you a that's thyroid And mentioned how physicians and But today dramatically is drugs, read controlled TED market actually the is blocked on uncovered TEPEZZA-like label these say acute I if goes. of least lot we return. then the pretty and over the X at a the realize the marketplace. well the you doses I So the what's treatment symptoms what TEPEZZA it's by

lower things as seen roll treat it's the when if after show we've of enroll that quicker reasons see physicians at on an one, and and the some there patients curve. X-dose of effects doses over one And and not, the like you or side the to flattening the those to TED result of to and we in dose of But -- TEPEZZA number a the able the to have they maybe the idea a a in active response of they on able doses, in to their be the numbers regimen so one also -- is, they'll induce higher up before. we really with point just that

we we to of experience maintenance to subcu, both and approved, believe with so then start think centers So lot and but patient, a all the actually an be in of treat call will treated. after well we be you will you in or very lot people to don't -- the couple a see would line and positioned, of that treatment the it's it have way where we're could retreat it put diagnosed induction our infusion infused more obviously, product a obviously, have go who hands the better just being patients and for to flexibility the a once

we you a seeing you sort once is way of where understand the in is at the q.X or patient see could control, technology, have month So you weekly and real with shift significant to think the induction pretty least caregiver, go where from and under the hands the and acute going. get an not paradigm our dosing you differentiated of phase paradigm could maintenance there a actually that a TEPEZZA we potentially are we which get symptoms then to a signs

Jason Butler

Are TEPEZZA. that retreat then. treat to and physicians that with hearing Got they're from a yet it. follow-up And there that employing you I just guess

acute chronic in treatment Or are is and either getting phase? So that? too a phase the retreated just say it then to early patients in

Scott Myers

much pretty right you the it hit think head, I So on actually.

from TEPEZZA had So full anecdotally they times because get sidelined vaccines. COVID their been pandemic, during treating who multiple what the doses we then and hear to were start the physicians X for couldn't

of then given give the few up and So watch and limited to see and what them heard doses people were the few doses X, and home then they in do touch. a give basically they sometimes we've still and number have them more a say, they patient give or result is to had doses, they'll send stay of and would return

you -- we And if these infuse come you can start excuse and back these to can feel you hear results, me, again.

So it. from into into I the physician. it then heard It's give as needs one PRN no, a few a doses turning -- turn is it and patient almost like

how we're So Intel adjust we market. benefit so we go hindsight up that can foresight this of versus picking have we intel, the and use to do and to

Operator

is next from line [Operator Instructions] with Your of Rami Katkhuda LifeSci. the question

Rami Katkhuda

me. the guess, and Two access is then your looking in data? TEPEZZA changed can specific TED proven concept after for protocol? secondly, quick the influence I have physicians there ones with in reimbursement first, conversations chronic out anything that that chronic And the THRIVE-X you're for study market or payers, considerations with

Todd James

Yes.

that So design. the Phase the to THRIVE-X how specific chronic data III and impact could

results from That of of We preliminary have, very course, topline So how we Horizon. data. activity. that the to recently got was us think can we kind of think some could thinking some what high-level to helpful clinical Phase about III design for look like about prior

any be KOL one today, call trial and relative preliminary in the trial specific the then We considerations fully we would kind and necessary that be feedback if design, our make by it's that will to data kick and/or to necessary activity of thinking before off to I kind we we'll trial. informed that of but health seek impacts by either that and see not also the authority out informed then thing

we'll do course, that well. as Of

us be market getting it's intelligence data -- now for X early think I as just around to ago, access far Horizon too decisions following weeks really that from that. As chronic

And if to course, we'll we the we're be work and intel more from as of the appropriate so to in time. definitely something care that getting of start survey would that marketplace we're listening we give you far it that's then be do. things, real as for to as that intelligence hearing And take

Operator

from of the is Gavin question line next Your Clarke-Gartner.

Gavin Clark-Gartner

clinical on wanted for you duration pricing wondering the extended you data X more just circle mentioned. doses. the don't policies allow allow what in dynamic payer or retreatment and that you for a back TEPEZZA just to today, this future? approach than dynamic to I also to show Because explicitly I'm of how need the lot

Scott Myers

Yes.

we be to So going you approach different way. the you're to because take. obviously might using the have retreat subcu this treat But you pricing out could and would you a would when be -- shift from of when induction post-approval time -- -- be that very whole maintenance, the could the

they now a and you at reimbursement a have with X. of they heard But any the retreatment, time X today, the label a physicians next could at chronic drug. X is treated instead And get and can can are broader be referring So of have the this is on they is you disease, bid. from the resubmit label going with -- now their lot I've for TED, and what been to basically and is

So per they'll with think X of could and struggling and maybe half then about it's with about and then and kg. antagonism, XXX using smaller not with be with also cohort at quite our people you X their that where you high use -- like X full -- are X-dose the if are I very doses mg dose, X/X we

be lower or to it's whether a being treat able dose So a preferred regimens, doses with subcu with of infusion or approach. seems number to different retreat dose

Operator

turn have the time, for President to and reached At remarks. like Myers, Viridian's over back I the question-and-answer of closing would session. conclusion Scott now the call we this CEO, to

Scott Myers

Louisa afternoon. your and if touch to again, you. great Todd for Thank to happy and have you Thanks questions, to free a or this reach we evening. any you, out and operator, base with are time have feel thanks, follow-up Please everyone,

Operator

This call the concludes today. conference

lines. You Thank disconnect participating. for may now you your

Viridian Therapeutics (VRDN) 9 May 232023 Q1 Earnings call transcript